Related Experiment Video
Updated: Aug 19, 2026

Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions
Published on: August 2, 2018
Antisense-thioredoxin inhibits angiogenesis via pVHL-mediated hypoxia-inducible factor-1alpha degradation
Woo Jean Kim1, Heeyeong Cho, Sae-Won Lee
1Department of Molecular Biology, Pusan National University, Busan 609-735, Korea.
Abstract:
Thioredoxin (Trx), a small redox protein, is overexpressed in a number of tumors, however, its roles in tumor cells were not defined well. To investigate the effect of Trx, we transfected Trx or antisense Trx vectors into HT1080 cells. Trx-overexpressed HT1080 cells induced migration of endothelial cells through Flt-1 vascular endothelial growth factor (VEGF) receptor type-1. However, the migration was reduced by overexpression of antisense-Trx. To understand the relationship between Trx and hypoxia-induced angiogenesis, we observed the expression level of VEGF and hypoxia-inducible factor-1alpha (HIF-1alpha) after transfection of Trx. Overexpression of Trx also caused a significant increase of VEGF in protein and RNA levels under normoxic and hypoxic conditions. Moreover, transfection of Trx caused a dramatic increase in HIF-1alpha protein level under hypoxic condition. However, transfection of antisense-Trx markedly decreased HIF-1alpha and VEGF expression compared with controls. In addition, HIF-1alpha was not translocated from cytoplasm to nucleus in antisense-Trx overexpressing HT1080 cells. Further, we could detect the association of HIF-1alpha and pVHL in antisense-Trx transfectant HT1080 cells. Taken together, we suggest that Trx plays an important role in angiogenesis and, therefore, antisense-Trx might be applicable to the inhibition of tumor angiogenesis through the induction of pVHL-mediated HIF-1alpha degradation.
Insights
Thioredoxin (Trx) promotes tumor angiogenesis by increasing vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1alpha (HIF-1alpha). Antisense Trx inhibits this process by promoting HIF-1alpha degradation, suggesting a therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Thioredoxin (Trx) is overexpressed in many tumors, but its precise function in cancer cells remains unclear.
- Understanding Trx's role is crucial for developing targeted cancer therapies.
Purpose of the Study:
- To investigate the effect of Thioredoxin (Trx) on tumor cell migration and angiogenesis.
- To elucidate the relationship between Trx, vascular endothelial growth factor (VEGF), and hypoxia-inducible factor-1alpha (HIF-1alpha) in cancer.
Main Methods:
- Transfection of Trx or antisense Trx vectors into HT1080 cells.
- Assessment of endothelial cell migration.
- Quantification of VEGF and HIF-1alpha protein and RNA levels under normoxic and hypoxic conditions.
- Analysis of HIF-1alpha translocation and interaction with pVHL.
Main Results:
- Trx overexpression enhanced endothelial cell migration and increased VEGF and HIF-1alpha levels.
- Antisense Trx reduced cell migration and decreased HIF-1alpha and VEGF expression.
- Antisense Trx inhibited HIF-1alpha nuclear translocation and promoted its association with pVHL.
Conclusions:
- Trx plays a significant role in promoting tumor angiogenesis.
- Antisense Trx may be a potential therapeutic agent for inhibiting tumor angiogenesis via pVHL-mediated HIF-1alpha degradation.
More Related Videos
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Mechanism of Angiogenesis
The JAK-STAT Signaling Pathway
